Novo Nordisk A/S (NYSE:NVO) Shares Sold by Farmers & Merchants Trust Co of Chambersburg PA

Farmers & Merchants Trust Co of Chambersburg PA cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 1.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 18,310 shares of the company’s stock after selling 278 shares during the period. Farmers & Merchants Trust Co of Chambersburg PA’s holdings in Novo Nordisk A/S were worth $1,575,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC grew its stake in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares during the period. Mediolanum International Funds Ltd acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $98,765,000. DAVENPORT & Co LLC grew its position in shares of Novo Nordisk A/S by 75.1% in the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after purchasing an additional 451,641 shares during the period. Wellington Management Group LLP acquired a new stake in Novo Nordisk A/S in the 3rd quarter worth about $42,017,000. Finally, World Investment Advisors LLC boosted its holdings in Novo Nordisk A/S by 2,655.9% in the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock worth $33,388,000 after buying an additional 270,234 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $78.78 on Friday. The stock’s fifty day moving average is $89.91 and its two-hundred day moving average is $110.40. The firm has a market capitalization of $353.52 billion, a P/E ratio of 23.94, a price-to-earnings-growth ratio of 0.96 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.86 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.